Nearly 10 million people in the United States and Europe are at high risk of developing liver cancer. This growing number of individuals is primarily comprised of patients with cirrhosis (scarring of the liver), which has various causes, such as obesity leading to
Early detection of liver cancer enables access to curative treatments such as ablation, resection, and transplants. Clinical best practice is for high risk patients to undergo biannual screening using ultrasound; however, the results are often insufficiently sensitive to detect early-stage cancers.
Mursla Bio is conducting a clinical study involving approximately 500 patients to validate a novel in vitro diagnostic (IVD) test to meet this clinical need.
Mursla Bio's cutting-edge technology isolates and analyses rare, tissue-specific EVs in blood, such as those originating from the liver, with unmatched precision. This enables non-invasive tissue biopsy of a patient at any time, detecting molecular disease patterns, like cancer, at their onset or recurrence.
Furthermore, our approach extends across multiple 'omics' such as RNA and protein, surpassing the less deterministic DNA that has driven the first generation of cancer liquid biopsy tests.
This breakthrough is made possible by our innovative biomarker discovery platform, coupled with scalable assays that enable the clinical application of newly identified biomarkers. It features a suite of proprietary and patented innovations.
